Business Context and Reporting Period
Lunai Bioworks Inc. (LNAI) filed a Current Report on Form 8-K on September 18, 2025. The filing details a material corporate action approved by stockholders on August 15, 2025, and filed with the Delaware Secretary of State on September 18, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure adjustment.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-10 reverse stock split of its common stock, effective September 29, 2025.
- Share Count Reduction: Outstanding shares decreased from 231,780,434 to approximately 23,178,096 shares.
- Fractional Shares: No fractional shares were issued; any fractions were rounded up to the next whole share.
- Trading Details: Trading on a split-adjusted basis began on September 30, 2025, on The Nasdaq Capital Market under the symbol "LNAI" with a new CUSIP number (29350E203).
- Authorized Shares: The number of authorized common shares remains unchanged at 350,000,000.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard incorporation by reference to the Certificate of Amendment and the proxy statement filed on July 30, 2025.
Investor Verification Checklist
- Verify the new CUSIP number (29350E203) for trading and settlement purposes.
- Confirm the adjusted share count in brokerage accounts following the September 29, 2025 effective date.
- Review the proxy statement (Form DEF 14A) filed on July 30, 2025, for the full rationale behind the reverse split.
- Monitor the stock price on September 30, 2025, to ensure it reflects the 1-for-10 adjustment.